Rheumatology

Immune Checkpoint Inhibitor

Questions discussed in this category

For ICI arthritis, how soon do you start DMARDs?

Is there evidence for development of more severe autoimmune toxicities for young patients vs older patients on immune checkpoint inhibitors?

As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays...

1 Answer available

Can JAK inhibitors for established rheumatoid arthritis be continued when starting an immune checkpoint inhibitor?

2 Answers available

How would you manage immune check point inhibitor induced capillary leak syndrome refractory to IVIG monotherapy?

1 Answer available

Papers discussed in this category

Journal for immunotherapy of cancer, 2022 Jan

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition.

Clinical rheumatology, 2020 Sep 28

Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?

Frontiers in immunology, 2022 Sep 15

Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib.

Cancer cell, 2022 May 09

Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.

Best Pract Res Clin Rheumatol, 2022 Dec

Treatment of rheumatic adverse events of cancer immunotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Sep 05

Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.

Frontiers in oncology, 2020 Apr 22

Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer.

Rheumatology

Immune Checkpoint Inhibitor

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology